University of Extremadura, CACERES, Spain; Julian F. Calderon-Garcia, PhD, Metabolic Bone Diseases Research Group. University of Extremadura, CACERES, Spain; Juan D. Pedrera-Zamorano, PhD, Metabolic Bone Diseases Research Group. University of Extremadura, CACERES, Spain We aimed to evaluate hypertension (HTA), hypercholesterolemia (HC) and both conditions simultaneously in postmenopausal Spanish women with and without low bone mineral density (BMD)

while controlling for the influence of confounding factors such BMI and age. A total of 1557 postmenopausal Spanish women aged 57.67 ± 7.95 years were analyzed. Within the studied population, Vorinostat mouse 245 women had a Dibutyryl-cAMP diagnosis of HTA, 290 of HC and 221 of both diseases. All the women had undergone treatment for see more these conditions at least during the last year. The remaining women (n = 801) conformed a without treatment group. HTA and HC were included as covariates in a logistic regression model assessing the relationship

between these conditions and both osteoporosis and low BMD while controlling for osteoporosis confounding factors. Specific mean BMD values at the femoral neck (FN) and spine provided by the DXA equipment manufacturer (Norland Corp. Fort Atkinson, WI, USA) were used to establish specific low BMD T-scores and osteoporosis diagnosis according to the WHO T-score criteria. Low BMD was defined as T score < −1 and normal BMD was defined as T score > or =−1. HTA and HC were not osteoporosis risk factors (crude odds ratio [OR] = 1.076; 95 % CI, 0.798–1.451; P = 0.631 for HTA; [OR] = 0.849; 95 % CI, 0.634–1.136; P = 0.271 for HC; [OR] = 1.082; 95 % CI, 0.731–1.599; P = 0.694

for both). Absence of significance remained after adjustment for potential confounding factors (adjusted odds ratio [OR] =1.206; 95 % CI, 0.822–1.767; P = 0.338 for HTA; [OR] = 0.849; 95 % CI, 0.634–1.136; P = 0.271 for HC; [OR] = 1.082; 95 % CI, 0.731–1.599; P = 0.694 for both). Without Megestrol Acetate adjustment HTA, HC or both were not associated with low BMD among Spanish women (crude odds ratio [OR] = 0.837; 95 % CI, 0.670–1.045; P = 0.117; [OR] = 1.065; 95 % CI, 0.855–1.326; P = 0.575; [OR] = 0.859; 95 % CI, 0.642–1.149; P = 0.306 respectively). After adjustment for potential confounding factors, HTA became a protective factor for low BMD (adjusted [OR] = 0.737; 95 % CI, 0.565–0.962; P = 0.025) but HC remained not significant (adjusted [OR] = 0.247; 95 % CI, 0.688–1.101; P = 0.247). Presence of the two conditions simultaneously remained as a protective factor (adjusted [OR] = 0.683; 95 % CI, 0.429–0.948; P = 0.023). Analysis of low BMD at the FN revealed HC as a risk factor (crude [OR] = 1.439; 95 % CI, 1.149–1.802; P = 0.002) but after adjustment the association remained no longer significant (adjusted [OR] = 0.813; 95 % CI, 0.607–1.088; P = 0.163). No other significant relationships were observed with the low BMD at the femur or the spine.